Mathias Susan D, Crosby Ross D, Rosén Karin E, Zazzali James L
Health Outcomes Solutions, Winter Park, Florida, USA.
Allergy Asthma Proc. 2015 Sep-Oct;36(5):394-8. doi: 10.2500/aap.2015.36.3873.
The Urticaria Patient Daily Diary (UPDD) is a validated patient-reported outcome that captures key measures of urticaria disease activity.
To update estimates of the minimal important difference (MID) for urticaria disease activity measures in the UPDD, including the weekly itch severity score, weekly number of hives score, weekly average size of largest hive score, and the composite measure of itch severity and number of hives over 7 days, or urticaria activity score 7 (UAS7).
A total of 975 subjects with chronic idiopathic urticaria from three randomized, double-blind, placebo-controlled studies completed the UPDD and other patient-reported outcome assessments (the Dermatology Life Quality Index, Medical Outcomes Study Sleep Scale, the Chronic Urticaria Quality-of-Life Questionnaire, the EuroQoL-5 Dimension Questionnaire) multiple times. MIDs were estimated through a combination of distribution- and anchor-based methods.
MID estimates ranged from 4.5 to 5.0 for the weekly itch severity score, 5.0 to 5.5 for weekly hives count score, 9.5 to 10.5 for the UAS7, and 4.0 to 4.5 for the weekly size of the largest hive score.
This analysis provided confirmation of the previous MID estimates for the urticaria disease activity measures in the UPDD.
荨麻疹患者每日日记（UPDD）是一种经过验证的患者报告结局，可获取荨麻疹疾病活动的关键指标。
更新UPDD中荨麻疹疾病活动指标的最小重要差异（MID）估计值，包括每周瘙痒严重程度评分、每周风团数量评分、每周最大风团平均大小评分以及7天内瘙痒严重程度与风团数量的综合指标，即荨麻疹活动评分7（UAS7）。
来自三项随机、双盲、安慰剂对照研究的975名慢性特发性荨麻疹患者多次完成UPDD及其他患者报告结局评估（皮肤病生活质量指数、医学结局研究睡眠量表、慢性荨麻疹生活质量问卷、欧洲五维健康量表）。通过基于分布和锚定的方法相结合来估计MID。
每周瘙痒严重程度评分的MID估计值范围为4.5至5.0，每周风团计数评分的MID估计值范围为5.0至5.5，UAS7的MID估计值范围为9.5至10.5，每周最大风团大小评分的MID估计值范围为4.0至4.5。
该分析证实了之前对UPDD中荨麻疹疾病活动指标的MID估计值。
